钆基磁共振造影剂的即时不良反应：对10608例检查的回顾性分析

Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations.

作者信息

Granata Vincenza, Cascella Marco, Fusco Roberta, dell'Aprovitola Nicoletta, Catalano Orlando, Filice Salvatore, Schiavone Vincenzo, Izzo Francesco, Cuomo Arturo, Petrillo Antonella

机构信息

Department of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale Tumori "Fondazione G. Pascale" IRCCS, 80131 Naples, Italy.

Department of Anesthesia, Endoscopy and Cardiology, Istituto Nazionale Tumori "Fondazione G. Pascale" IRCCS, 80131 Naples, Italy.

出版信息

Biomed Res Int. 2016;2016:3918292. doi: 10.1155/2016/3918292. Epub 2016 Aug 29.

DOI:10.1155/2016/3918292

PMID:27652261

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5019936/

Abstract

Background and Purpose. Contrast media (CM) for magnetic resonance imaging (MRI) may determine the development of acute adverse reactions. Objective was to retrospectively assess the frequency and severity of adverse reactions associated with gadolinium-based contrast agents (GBCAs) injection in patients who underwent MRI. Material and Methods. At our center 10608 MRI examinations with CM were performed using five different GBCAs: Gd-BOPTA (MultiHance), Gd-DTPA (Magnevist), Gd-EOBDTPA (Primovist), Gd-DOTA (Dotarem), and Gd-BTDO3A (Gadovist). Results. 32 acute adverse reactions occurred, accounting for 0.3% of all administration. Twelve reactions were associated with Gd-DOTA injection (0.11%), 9 with Gd-BOPTA injection (0.08%), 6 with Gd-BTDO3A (0.056%), 3 with Gd-EOB-DTPA (0.028%), and 2 with Gd-DTPA (0.018%). Twenty-four reactions (75.0%) were mild, four (12.5%) moderate, and four (12.5%) severe. The most severe reactions were seen associated with use of Gd-BOPTA, with 3 severe reactions in 32 total reactions. Conclusion. Acute adverse reactions are generally rare with the overall adverse reaction rate of 0.3%. The most common adverse reactions were not severe, consisting in skin rash and hives.

摘要

背景与目的。磁共振成像（MRI）造影剂（CM）可能会引发急性不良反应。目的是回顾性评估接受MRI检查的患者注射钆基造影剂（GBCA）后不良反应的发生率和严重程度。材料与方法。在我们中心，使用五种不同的GBCA进行了10608次使用CM的MRI检查：钆贝葡胺（MultiHance）、钆喷酸葡胺（马根维显）、钆塞酸二钠（普美显）、钆特酸（Dotarem）和钆布醇（Gadovist）。结果。发生了32例急性不良反应，占所有给药病例的0.3%。12例反应与钆特酸注射有关（0.11%），9例与钆贝葡胺注射有关（0.08%），6例与钆布醇有关（0.056%），3例与钆塞酸二钠有关（0.028%），2例与钆喷酸葡胺有关（0.018%）。24例反应（75.0%）为轻度，4例（12.5%）为中度，4例（12.5%）为重度。最严重的反应与钆贝葡胺的使用有关，在32例总反应中有3例严重反应。结论。急性不良反应通常很少见，总体不良反应率为0.3%。最常见的不良反应不严重，表现为皮疹和荨麻疹。